BioInvent International AB (BOVNF)
4.70
0.00 (0.00%)
USD |
OTCM |
May 17, 16:00
BioInvent International Cash from Financing (TTM): -0.8002M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | -0.8002M |
| December 31, 2023 | 2.186M |
| September 30, 2023 | 3.369M |
| June 30, 2023 | 30.17M |
| March 31, 2023 | 30.22M |
| December 31, 2022 | 27.27M |
| September 30, 2022 | 26.99M |
| June 30, 2022 | -2.584M |
| March 31, 2022 | -3.024M |
| December 31, 2021 | 104.55M |
| September 30, 2021 | 108.12M |
| June 30, 2021 | 167.69M |
| March 31, 2021 | 177.97M |
| December 31, 2020 | 70.41M |
| September 30, 2020 | 66.26M |
| June 30, 2020 | 9.229M |
| March 31, 2020 | 22.54M |
| December 31, 2019 | 22.70M |
| September 30, 2019 | 22.79M |
| June 30, 2019 | 22.98M |
| March 31, 2019 | 8.815M |
| December 31, 2018 | 9.256M |
| September 30, 2018 | 8.981M |
| June 30, 2018 | 9.280M |
| March 31, 2018 | 0.4512M |
| Date | Value |
|---|---|
| December 31, 2017 | 0.00 |
| September 30, 2017 | 6.180M |
| June 30, 2017 | 5.254M |
| March 31, 2017 | 30.83M |
| December 31, 2016 | 30.83M |
| September 30, 2016 | 24.71M |
| June 30, 2016 | 25.57M |
| March 31, 2016 | 8.018M |
| December 31, 2015 | 8.018M |
| September 30, 2015 | 8.098M |
| June 30, 2015 | 7.728M |
| March 31, 2015 | 8.391M |
| December 31, 2014 | 8.391M |
| September 30, 2014 | 8.270M |
| June 30, 2014 | 11.67M |
| March 31, 2014 | 2.978M |
| December 31, 2013 | 2.978M |
| September 30, 2013 | 2.910M |
| June 30, 2013 | 0.3498M |
| March 31, 2013 | 14.26M |
| December 31, 2012 | 14.26M |
| September 30, 2012 | 14.27M |
| June 30, 2012 | 13.20M |
| March 31, 2012 | 19.79M |
| December 31, 2011 | 19.79M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-3.024M
Minimum
Mar 2022
177.97M
Maximum
Mar 2021
45.45M
Average
24.98M
Median
Cash from Financing (TTM) Benchmarks
| Abliva AB | 0.0391M |
| Karolinska Development AB | -0.0782M |
| Calliditas Therapeutics AB | -- |
| Oncopeptides AB | 11.82M |
| Olink Holding AB | -2.973M |